For example, the Clinical Pharmacogenomics Implementation Consortium ... Data must then be presented and approved before the updated testing kit can be released. A challenge of IVDR is the ...

Point-of-care DNA testing is now starting. Risk and probability are more difficult concepts in genotypic versus phenotypic assays. Appropriate evaluation of pharmacogenomic tests is a high ...

New research shows almost 90% of people in England would agree to genetic testing to get the most ... 85% thought that the NHS should offer pharmacogenomic testing to people with multiple health ...

The program will use NalaGenetics' PGx test to screen leprosy patients for the HLA-B*13:01 allele, which has been linked with a serious hypersensitivity reaction.